<DOC>
	<DOCNO>NCT01437774</DOCNO>
	<brief_summary>The ReStore™ Thrombectomy device restores blood flow neurovascular remove thrombus patient experience ischemic stroke . Patients enrol ReStore Trial randomize treatment ReStore™ Thrombectomy Device ( investigational treatment ) treatment commercially available thrombectomy device It expect investigational treatment safety profile term clinically significant procedural adverse event comparable control group .</brief_summary>
	<brief_title>ReStore Thrombectomy Trial Flow Restoration Acute Ischemic Stroke Patients</brief_title>
	<detailed_description>The objective study demonstrate substantial equivalence ReStore™ Thrombectomy Device legally market MERCI Retrieval System . The study evaluate safety efficacy ReStore™ Thrombectomy Device subject diagnose acute ischemic stroke require mechanical thrombectomy . All eligible patient enrol randomized treatment either investigational therapy control therapy .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Age ≥ 22 ≤ 85 year Clinical sign consistent diagnosis acute ischemic stroke Prestroke Modified Rankin Score ≤2 National Institute Health Stroke Scale ( NIHSS ) assessment score ≥8 &lt; 30 Patient present 0 8 hour onset stroke symptom Contraindicated IV tPA treatment ( specify drug manufacturer 's IFU ) OR Acute ischemic stroke treat intravenous thrombolytic therapy vascular imaging ( TCD , CTA , MRA , angiography ) show persistent occlusion end infusion treatment . NOTE : Treatment initiate within 8 hour symptom onset ( first retrieval pas make within 8 hour ) Neurologic sign NOT rapidly improve ( NIHSS score NOT decrease 4 point determine prior time treatment compare initial screen ; TIMI 0 1 flow internal carotid , middle cerebral M1/M2 segment , basilar , vertebral artery confirm angiography accessible retrieval device . Patient/patient legal authorize representative willing comply protocol requirement return treatment center require clinical evaluation Patient legally authorize representative give informed consent , consent document . NIHSS ≥30 comatose Known pregnant Serum glucose level &lt; 50 mg/dL Excessive cervical arterial tortuousity prevents placement retrieval device Known hemorrhagic diathesis Patients exhibit sign suggestive angiographic evidence bilateral stroke Coagulation factor deficiency ( oral anticoagulation therapy INR &gt; 3.0 ) In receipt heparin within 48 hour PTT &gt; 2x lab normal Baseline platelet &lt; 30,000 mm3 Known serious sensitivity intraarterial radiographic contrast agent Severe sustain hypertension ( systolic blood pressure &gt; 185 mmHg diastolic &gt; 110 mmHg ) Baseline CT MRI reveal significant mass effect midline shift great 1/3 MCA region hypodensity ( sulcal effacement and/or loss graywhite differentiation allow ) Neurologic sign rapidly improve time treatment measure decrease NIHSS score 4 point determine prior time treatment compare initial screen CT MRI evidence hemorrhage presentation CT MRI evidence mass effect intracranial tumor ( except small meningioma ) Life expectancy &lt; 3 month Angiographic evidence carotid dissection , high grade stenosis ( &gt; 50 % stenosis artery proximal target vessel ) prevent access clot , vasculitis At discretion investigator , patient comorbidities associate life expectancy le 3 month comorbidities could influence study result make clinical followup difficult exclude .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Acute ischemic stroke</keyword>
</DOC>